Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

Hemorrhage Following Small Polyp Resection in the Colon in Anticoagulated Patients

First Posted Date
2015-03-02
Last Posted Date
2015-03-02
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
286
Registration Number
NCT02375646

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

First Posted Date
2015-01-28
Last Posted Date
2018-01-29
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
678
Registration Number
NCT02348723
Locations
🇺🇸

Mercy Medical Group, a service of Dignity Health Medical Foundation, Sacramento, California, United States

🇺🇸

Southwest Florida Research, LLC, Naples, Florida, United States

🇺🇸

University of California, San Francisco, California, United States

and more 83 locations

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

First Posted Date
2015-01-26
Last Posted Date
2015-03-10
Lead Sponsor
Boehringer Ingelheim
Registration Number
NCT02345304
Locations
🇩🇪

1344.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation

Not Applicable
Recruiting
Conditions
Interventions
First Posted Date
2014-12-17
Last Posted Date
2024-04-15
Lead Sponsor
Cedars-Sinai Medical Center
Target Recruit Count
3000
Registration Number
NCT02318342
Locations
🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-12-02
Last Posted Date
2014-12-02
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
20
Registration Number
NCT02305030

RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial

Phase 2
Completed
Conditions
Interventions
First Posted Date
2014-12-01
Last Posted Date
2022-04-12
Lead Sponsor
Hospital do Coracao
Target Recruit Count
1005
Registration Number
NCT02303795
Locations
🇧🇷

Associação do Sanatório Sírio - Hospital do Coração HCor, São Paulo, SP, Brazil

Use of Warfarin After the First Trimester in Pregnant Women With APS

First Posted Date
2014-11-27
Last Posted Date
2023-10-31
Lead Sponsor
Mohamed Sayed Abdelhafez
Target Recruit Count
100
Registration Number
NCT02303171
Locations
🇪🇬

Obstetrics and Gynecology Department in Mansoura University Hospital, Mansourah, Dakahlia, Egypt

🇪🇬

Private practice settings, Mansourah, Dakahlia, Egypt

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome

First Posted Date
2014-11-20
Last Posted Date
2023-09-28
Lead Sponsor
Scott C. Woller, MD
Target Recruit Count
48
Registration Number
NCT02295475
Locations
🇺🇸

The James Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Intermountain Medical Center, Murray, Utah, United States

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-11-10
Last Posted Date
2014-12-01
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
13
Registration Number
NCT02287415

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

First Posted Date
2014-11-05
Last Posted Date
2021-11-30
Lead Sponsor
University of South Florida
Target Recruit Count
91
Registration Number
NCT02283294
Locations
🇺🇸

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States

🇺🇸

Bayfront Health St Petersburg, Saint Petersburg, Florida, United States

🇺🇸

University of Louisville, Louisville, Kentucky, United States

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath